REGN vs TRVI
REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases. TRVI: Trevi Therapeutics is a clinical-stage biopharma company developing its lead product candidate, Haduvio, to treat challenging chronic pruritus and chronic cough conditions.
Side-by-side fundamentals
| Metric | REGN | TRVI | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $828.50 | $17.96 | |
| Market cap as of 2026-08-24 | $77.8B | $2.6B | |
| P/E as of 2026-08-24 | 20.48 | n/a | |
| PEG as of 2026-08-24 | 1.08 | n/a | |
| Net margin as of 2026-08-24 | +27.9% | n/a | |
| Gross margin as of 2026-08-24 | +86.0% | n/a | |
| Operating margin as of 2026-08-24 | +24.7% | n/a | |
| ROE as of 2026-08-24 | +13.8% | -23.6% | REGN higher |
| ROA as of 2026-08-24 | +10.6% | -22.6% | REGN higher |
| Debt / equity as of 2026-08-24 | 0.09 | 0.00 | TRVI lower |
| Revenue growth (YoY) as of 2026-08-24 | +9.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +5.6% | n/a | |
| Dividend yield as of 2026-08-24 | +0.5% | n/a | |
| Beta as of 2026-08-24 | 0.62 | 0.92 | |
| 1-year return as of 2026-08-24 close | +40.5% | +139.8% | TRVI higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.